Related Experiment Video
Updated: May 8, 2026
10:46
A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Teriflunomide in relapsing multiple sclerosis: therapeutic utility.
1Department of Medicine (Neurology), University of Ottawa, Senior Scientist, The Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON, Canada K1H 8L6.
Therapeutic Advances in Chronic Disease
|September 3, 2013
Summary
Teriflunomide is an effective oral therapy for relapsing multiple sclerosis (RMS). This disease-modifying therapy (DMT) reduces relapses and disability progression with a favorable safety profile.
Area of Science:
- Neurology
- Immunology
- Pharmacology
Background:
- Multiple Sclerosis (MS) is a chronic inflammatory disease of the central nervous system.
- Relapsing forms of MS (RMS) are characterized by distinct attacks and remissions.
- Disease-modifying therapies (DMTs) are crucial for managing MS progression.
Purpose of the Study:
- To review the efficacy and safety of teriflunomide for treating RMS.
- To evaluate teriflunomide's impact on clinical and MRI outcomes in RMS patients.
- To assess the long-term benefits and tolerability of teriflunomide therapy.
Main Methods:
- Review of an extensive clinical development program for teriflunomide.
- Analysis of clinical trial data assessing relapse rates and disability progression.
- Evaluation of magnetic resonance imaging (MRI) outcomes.
- Assessment of teriflunomide's safety and tolerability profile.
Main Results:
- Teriflunomide demonstrated consistent benefits on clinical and MRI outcomes in RMS.
- Long-term studies showed low rates of relapse and disability progression up to 8 years.
- Adverse events were generally mild to moderate and rarely led to discontinuation.
Conclusions:
- Teriflunomide is an effective oral, once-daily DMT for RMS.
- It offers consistent benefits in managing MS, with a well-characterized safety profile.
- Teriflunomide represents a valuable addition to the available DMTs for RMS treatment.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.